Know Cancer

forgot password

A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75

Phase 2
18 Years
Not Enrolling
Bladder Cancer

Thank you

Trial Information

A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75

OUTLINE: This is a multi-center study.

- Cisplatin 70 mg/m2 Day 1

- Gemcitabine 1250 mg/m2 Day 1 and 8

- Bevacizumab 15 mg/kg Day 1

Review toxicity every cycle (every 3 weeks) Review for radiographic response every 2 cycles
(every six weeks)

Progressive disease = off protocol therapy

Patients will be treated for up to a maximum of 8 cycles of cisplatin and gemcitabine (24
weeks of therapy). If a patient has not progressed by the end of 24 weeks (completion of
cisplatin and gemcitabine), then patient will be treated with bevacizumab at 15 mg/kg every
three weeks for a maximum of 12 months of bevacizumab therapy (since study entry).

If at any time patient has undue toxicity or progressive disease, patient will be removed
from the study and followed until progression and for survival.

If the patient has Grade 3 or 4 neurotoxicity and/or the creatinine rises above 2.0, then
the cisplatin will be discontinued and the patient continued on study and treated with
gemcitabine and bevacizumab at the same dose and schedule.

ECOG Performance Status 0 or 1


- White blood cell count > 3000/mm3

- Absolute neutrophil count (ANC) > 1500 mm/3

- Platelet count > 100,000/mm3

- Hemoglobin > 8 g/dL (may be transfused or receive erythropoietin support to maintain or
exceed this level).

- INR < 1.5

- No full dose/therapeutic anticoagulation with either low molecular weight heparin or
unfractionated heparin or coumadin


- Total bilirubin of <1.5 mg/dL

- ALT <5 times upper limit of normal for subjects with documented liver metastases; <2.5
times the upper limit of normal for subjects without evidence of liver metastases.


- Serum creatinine of < 1.5 mg/dL.

- Urine protein:creatinine ratio < 1.0 at screening


- No history of myocardial infarction or stroke within the last 6 months

- No uncontrolled hypertension (blood pressure of >160 systolic and/or 110 diastolic mmHg
on medication)

- No unstable angina, New York Heart Association (NYHA) Grade II or greater congestive
heart failure

- No unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial
arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are
eligible), or clinically significant peripheral vascular disease.


- Not specified

Inclusion Criteria:

- Previously untreated or relapsed locally advanced or metastatic transitional cell
carcinoma of the bladder. (Patients with pathology showing ANY component of
non-transitional cell histology are not eligible).

- Relapsed patients may have received prior chemotherapy ≥ one year prior to study
registration as part of a neoadjuvant or adjuvant regimen and must not have had
intervening therapy from the end of that treatment until study entry.

- Measurable disease as per RECIST.

- Prior radiation therapy, immunotherapy, cytokine, biologic or vaccine therapy must be
greater than 28 days prior to being registered for protocol therapy,

Exclusion Criteria:

- No known central nervous system metastasis. (imaging of brain only required if
clinically indicated)

- No prior organ allograft.

- No history of other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates the use of an investigational drug or that might affect the
interpretation of the results of the study or render the subject at high risk from
treatment complications.

- No evidence of bleeding diathesis or coagulopathy.

- No history of serious, non-healing wound, ulcer or bone fracture

- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to being registered for protocol therapy.

- No prior history of malignancy in the past 5 years with the exception of basal cell
and squamous cell carcinoma of the skin. Other cancers with low potential for
metastasis, such as in situ cancers (e.g., Grade 1, TA TCC (low grade superficial
bladder cancer), colonic polyp with focus of adenocarcinoma) can also be enrolled
after approval from the study chair.

- No major surgical procedure, open biopsy, or significant traumatic injury less than
28 days prior to being registered for protocol therapy.

- Patients are not eligible if the need for any major surgical procedure is anticipated
during the course of the study.

- Any minor surgical procedures, fine needle aspirations or core biopsies must be
greater than 7 days prior to being registered for protocol therapy except procedures
to secure a vascular access device which must be greater than 7 days prior to the
start of protocol therapy.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

- To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab.

Outcome Time Frame:

36 months

Safety Issue:


Principal Investigator

Christopher Sweeney, M.B.B.S.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group, LLC


United States: Institutional Review Board

Study ID:

HOG GU04-75



Start Date:

November 2005

Completion Date:

December 2008

Related Keywords:

  • Bladder Cancer
  • Urinary Bladder Neoplasms



Indiana University Cancer Center Indianapolis, Indiana  46202-5265
Siteman Cancer Center Saint Louis, Missouri  63110
University of Chicago Chicago, Illinois  60637
Oncology Hematology Care, Inc. Cincinnati, Ohio  45219
Arnett Cancer Care Lafayette, Indiana  47904
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Medical & Surgical Specialists, LLC Galesburg, Illinois  61401
Oncology Hematology Associates of SW Indiana Evansville, Indiana  47714
Quality Cancer Center (MCGOP) Indianapolis, Indiana  46202
AP&S Clinic Terre Haute, Indiana  47804
Fort Wayne Oncology & Hematology, Inc Fort Wayne, Indiana  46815